Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCwm, Llc
Latest Disclosed Ownership11,580 shares
Latest Disclosed Value $ 3,831,498
Cwm, Llc reports 54.54% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Cwm, Llc filed a 13F-HR form disclosing ownership of 11,580 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $3,308,406 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 25,475 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -54.54% during the quarter. The current value of the position is $2,915,844 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,580 -13,895 -54.54 3,831 38,210.00 0.0100
2026-01-26 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,475 -3,812 -13.02 10 -23.08 0.0274
2025-10-15 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,287 23,775 431.33 13 1,200.00 0.0402
2025-07-25 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,512 -11,152 -66.92 2 -75.00 0.0063
2025-05-01 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,664 3,473 26.33 4 33.33 0.0179
2025-02-04 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,191 6,427 95.02 3 200.00 0.0129
2024-10-08 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,764 3,272 93.70 2 0.0080
2024-07-10 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,492 1,770 102.79 1 0.0040
2024-04-05 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,722 -41,678 -96.03 0 -100.00 0.0012
2024-02-01 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,400 -538 -1.22 8 14.29 0.0447
2023-10-11 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,938 -1,436 -3.16 8 -12.50 0.0477
2023-08-03 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,374 43,648 2,528.85 9 0.0533
2023-05-01 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,726 -193 -10.06 0 0.0023
2023-02-01 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,919 -1,044 -35.23 0 -100.00 0.0034
2022-10-27 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,963 -410 -12.16 593 20.53 0.0047
2022-07-28 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,373 -6,579 -66.11 492 -69.72 0.0038
2022-04-21 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,952 -2,046 -17.05 1,625 -20.15 0.0115
2022-01-31 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,998 102 0.86 2,035 0.89 0.0143
2021-09-15 2021-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2021-07-29 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 2,017 0.0161
2021-09-15 2021-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2021-04-27 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 800 -11,096 113 0.0010
2021-09-15 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2021-01-27 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 700 -11,196 91 0.0009
2021-09-15 2020-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2020-10-19 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 650 -11,246 95 0.0011
2021-09-15 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2020-07-22 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 656 -11,240 97 0.0012
2021-09-15 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2020-04-28 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 550 -11,346 60 0.0009
2021-09-14 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2020-01-27 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 585 -11,311 67 0.0009
2021-09-14 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2019-10-22 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 585 -11,311 47 0.0007
2021-09-14 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 0 0.00 2,017 0.00 0.0161
2019-07-31 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35 -11,861 3 0.0000
2021-09-02 2019-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,896 11,896 2,017 0.0161
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.